756 results about "Interleukin" patented technology

The invention relates to the technical field of biological products, and discloses a mesenchymal stem cell hair growth liquid and a preparation method thereof, and the mesenchymal stem cell hair growth liquid comprises the following components: hair follicle mesenchymal stem cells; a hair follicle mesenchymal stem cell exosome; growth factors: a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGFs), a keratinocyte growth factor (KGF-7) and interleukin-10 (IL-10); vitamins: vitamin E, vitamin B5, vitamin B2, vitamin B6, vitamin C and biotin; the plant extracts comprise a cacumen biotae extract, a polygonum multiflorum extract, a ginseng extract, a peppermint extract, a purslane extract and a rhodiola rosea extract; other active ingredients: tripeptide and digoxin; the auxiliary material is a hyaluronic acid-collagen peptide graft copolymer; and the balance of a phosphate buffer solution.

The invention belongs to the technical field of chemical drugs, provides an interleukin-17A / F inhibitor as well as a preparation method and application thereof, and particularly relates to a compound as shown in a general formula (I), or a racemate, an isomer or medicinal salt thereof, which is used for treating diseases such as psoriasis and arthritis as the IL-17A / F inhibitor.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The application discloses an electrochemiluminescence immunosensor for detecting interleukin-1 beta and a preparation method and application thereof, and comprises a three-electrode system of a working electrode, a reference electrode and a counter electrode; the working electrode is a modified electrode of CoAl layered double hydroxide, is loaded with platinum nanoparticles after being etched by alkali, and is obtained by fixing interleukin-1 beta antibodies and blocking non-specific sites; and a solution containing luminol is used as an electrolyte during detection of the immunosensor. The working electrode of the immunosensor takes oxygen-rich vacancy CoAl layered double hydroxide as a substrate, combines with platinum nanoparticles to realize EMSI effect, significantly enhances the electrochemiluminescence signal of a luminol-dissolved oxygen system, realizes quantitative detection of IL-1 beta by combining with specific antigen-antibody recognition, and has the characteristics of strong anti-interference ability, fast detection speed and good stability.

Provided herein are engineered proteins and methods of treating using the engineered proteins, wherein the engineered proteins comprise a first region and a second region, wherein the first region binds TREM1, a variant thereof or a functional fragment thereof, and wherein the second region binds an interleukin, wherein the interleukin comprises a protein selected from any one of IL-1 family, IL-6 family, IL-12 family and IL-23 family, a variant thereof or a functional fragment thereof.

The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.

Several embodiments disclosed herein relate to methods and compositions for enhanced expansion of NK cells in culture, through the repeated co-culturing of NK cells with feeder cells and the selective use of stimulatory interleukins. In several embodiments, the methods utilize one or more soluble interleukins as culture media supplements at one or more time points during expansion of the NK cell, or other immune cell, which results in a highly expanded and highly cytotoxic population of cells, for use in, for example allogeneic cellular immunotherapy.

A recombinant NK-92 cell has a constitutive active promotor that effects expression of native CD16, and most preferably homogenous CD16 158V. Further contemplated recombinant NK-92 cells also include a recombinant nucleic acid that encodes an intracellularly retained interleukin (e.g., IL-2 or er-IL-2), wherein the recombinant NK-92 cell will secrete no more than 5,000 pg / mL IL-2 into a culture medium. The recombinant NK-92 cells presented herein have a significantly improved signal-to-noise ratio and exhibit reduced non-ADCC cytotoxicity.

The invention provides novel fusion proteins of Interleukin 15 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

Provided are methods of treating liver diseases comprising administering recombinant proteins comprising an interleukin-18-binding protein and an antigen binding fragment that binds to serum albumin.

The invention belongs to the technical field of biological medicines, and particularly relates to an anti-human interleukin-8 monoclonal antibody and application thereof. A heavy chain variable region of the monoclonal antibody comprises a CDR-H1 of which the amino acid sequence is shown as SEQ ID NO.3, a CDR-H2 of which the amino acid sequence is shown as SEQ ID NO.4 and a CDR-H3 of which the amino acid sequence is shown as SEQ ID NO.5; the light chain variable region comprises a CDR-L1 of which the amino acid sequence is as shown in SEQ ID NO.6, a CDR-L2 of which the amino acid sequence is as shown in SEQ ID NO.7 and a CDR-L3 of which the amino acid sequence is as shown in SEQ ID NO.8. The monoclonal antibody has good affinity to IL-8, can effectively block combination of IL-8 and a receptor CXCR1 / 2, and has a good treatment effect on IL-8-mediated diseases such as brain glioma and the like.

The present invention provides specific dosage regimens for the treatment of generalized pustular psoriasis (GPP) with anti-interleukin-36R antibodies (anti-IL36R antibodies) which dosage regimens surprisingly provide for the rapid and sustained remission of pathological symptoms of GPP including e.g., flares caused by GPP.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a benzofuran compound in dalbergia odorifera and a preparation method and application thereof.The benzofuran compound is separated from dalbergia odorifera of a leguminous dalbergia plant, the heartwood of the dalbergia odorifera is extracted and concentrated to obtain extract, and the extract is filtered to obtain the benzofuran compound. The extract is taken and sequentially subjected to silica gel column chromatography, medium-pressure ODS column chromatography and gel column chromatography separation for multiple times, then semi-preparative high performance liquid chromatography is used for purification, and the benzofuran compounds can be obtained. According to the present invention, lipopolysaccharide (LPS) is adopted to induce RAW 264.7 cells to establish an inflammation model, such that the compound has good anti-inflammatory activity, IC50 is 14.33 [mu] M, and expression of inflammatory factor interleukin-6 (IL-6) and interleukin-1 [beta] (IL-1 [beta]) can be inhibited;

The application belongs to the technical field of natural medicinal chemistry, and discloses a benzofuran compound in Jinyunming and a preparation method and application thereof. The benzofuran compound is separated from Jinyunming of the plant Dalbergia hupeana Tutch in the family of Leguminosae. The heartwood of Jinyunming is extracted and concentrated to obtain extract, the extract is sequentially separated by multiple silica gel column chromatography, medium-pressure ODS column chromatography and gel column chromatography, and then purified by semi-preparative high-performance liquid chromatography, so that the benzofuran compound can be obtained. The application establishes an inflammation model by inducing RAW 264.7 cells with lipopolysaccharide (LPS), and shows that the compound has good anti-inflammatory activity, the IC50 is 14.33 μM, and the expression of inflammatory factors interleukin-6 (IL-6) and interleukin-1β (IL-1β) can be inhibited.

Disclosed are a new interleukin-2 (IL-2) mutant protein and the use thereof. Compared with wild-type IL-2, the IL-2 mutant protein has improved properties, such as an improved IL-2 receptor binding property and improved druggability. Also provided are a fusion protein, dimer and immunoconjugate comprising the IL-2 mutant protein, nucleic acids encoding the IL-2 mutant protein, the dimer and the immunoconjugate, and a vector and host cell comprising the nucleic acid. Further provided are methods for preparing the IL-2 mutant protein, the fusion protein, the dimer and the immunoconjugate, a pharmaceutical composition containing same, and the therapeutic use thereof.

The application discloses a hybridoma cell strain secreting an anti-tilapia interleukin-2 monoclonal antibody and an application thereof, and the hybridoma cell strain 1C11F5 is preserved in the China Center for Type Culture Collection (CCTCC) on March 9, 2024, and the preservation number is CCTCC NO: C202470. The application can specifically identify the tilapia IL-2 protein and the lymphocyte group secreting IL-2, is helpful for further exploration of T cell activation and proliferation, and provides an important immunological tool for adaptive immune mechanism research of hard fish (such as tilapia and the like).

The invention discloses an electrochemical luminescence immunosensor for detecting interleukin-1 beta as well as a preparation method and application of the electrochemical luminescence immunosensor. The electrochemical luminescence immunosensor comprises a three-electrode system consisting of a working electrode, a reference electrode and a counter electrode, the working electrode is a modified electrode of CoAl layered double hydroxides, the modified electrode is subjected to alkali etching and then loaded with platinum nanoparticles, then an interleukin-1 beta antibody is fixed, and non-specific sites are closed, so that the working electrode is obtained; when the immunosensor is used for detection, a solution containing luminol is used as an electrolyte. The working electrode of the immunosensor takes oxygen vacancy-rich CoAl layered double hydroxide as a substrate, platinum nanoparticles are combined to realize an EMSI effect, an electrochemical luminescence signal of a luminol-dissolved oxygen system is remarkably enhanced, and antigen-antibody specific recognition is combined to realize quantitative detection of IL-1beta. The method has the characteristics of strong anti-interference capability, high detection speed and good stability.

Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The technology described herein is directed to methods of generating CD4+CD8- single-positive T cells from CD4+CD8+ double positive T progenitor cells using differentiation in the presence of interleukin-7 (IL-7) and an anti-CD3 agent and in absence of Notch ligand and an anti-CD28 agent. Also described herein are CD4+CD8- single-positive T cells made by the methods described herein, which can be used for therapeutic applications.

Disclosed herein is a method of treating an individual afflicted with moderate to severe ulcerative colitis, the method comprising: administering a local inhibitor of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-alpha) to an intestine of the individual.

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

This disclosure provides an antibody (or antigen-binding protein) comprising at least one, preferably two, antigen-binding domains that bind to the human IL-6 receptor, wherein the antibody inhibits IL-6 transsignaling via the human soluble IL-6 receptor while maintaining IL-6 classical signaling via the human membrane-bound IL-6 receptor, and the antibody is capable of binding to both the human soluble IL-6 receptor and the human membrane-bound IL-6 receptor. Compositions comprising the antibody or antigen-binding protein are also provided, along with encoding nucleic acid molecules and expression vectors.

To provide a new application for an oral composition comprising vesicles separated from a food fermented from soybeans using a bacterium belonging to the genus Bacillus.SOLUTION: An oral composition containing vesicles separated from a food fermented from soybeans using a bacterium belonging to the genus Bacillus is used for at least one application selected from the group consisting of suppression of interleukin-1β production, improvement of diseases associated with interleukin-1β, and prevention of diseases associated with interleukin-1β.SELECTED DRAWING: None

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.